Amgen vs AstraZeneca
Amgen (AMGN), health care, and AstraZeneca (AZN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
AstraZeneca is worth $283.9B on the stock market and Amgen $248.1B: AstraZeneca is valued at 14% more. Amgen trades at 26.6 times earnings and AstraZeneca at 25.9; operating margins in their latest fiscal years were 24.7% and 23.4%. Over the past year Amgen's share price has moved +34.4% and AstraZeneca's +2.75%.
Key facts
- Amgen market value
- $248.1B
- AstraZeneca market value
- $283.9B
- Amgen P/E
- 26.6
- AstraZeneca P/E
- 25.9
- Amgen revenue
- $36.8BFY to 2025-12-31
- AstraZeneca revenue
- $58.7BFY to 2025-12-31
- Superinvestors holding both
- 3
Market values as of .
| Measure | Amgen | AstraZeneca |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $248.1Blower | $283.9Bhigher |
| Revenue | $36.8Blower | $58.7Bhigher |
| Earnings | $7.7Blower | $10.2Bhigher |
| Employees | 31,500lower | 96,100higher |
| Total assets | $90.6Blower | $114.1Bhigher |
| Valuation | ||
| P/E | 26.6higher | 25.9lower |
| P/S | 6.8higher | 4.8lower |
| P/B | 17.3 | — |
| Dividend yield | 2.15% | — |
| Profitability | ||
| Operating margin | 24.7%higher | 23.4%lower |
| Balance sheet | ||
| Net assets | $8.7Blower | $48.7Bhigher |
| Total liabilities | $81.9Bhigher | $65.4Blower |
| Total debt | $54.6Bhigher | $29.6Blower |
| Cash on hand | $9.1Bhigher | $5.7Blower |
| Price change | ||
| Today | -0.80%lower | -0.52%higher |
| 1 year | +34.4%higher | +2.75%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (3)
- Primecap team1.5% / 1.8%
- Ken Fisher0.2% / 0.5%
- Dodge & Cox team<0.1% / <0.1%
Amgen only (7)
- Bill Smead5.3%
- Howard Gleicher2.6%
- Josef Lakonishok0.4%
- David Shaw (founder)0.3%
- Fred DiSanto0.2%
- Ken Griffin0.1%
- Mairs & Power team<0.1%
AstraZeneca only (9)
- Sarah Ketterer20.2%
- Lew Sanders1.1%
- Brandon Haley1.1%
- Larry Robbins0.7%
- Temasek0.4%
- Andrew Spokes0.4%
- Steve Cohen0.2%
- Polen Capital team<0.1%
- Rajiv Jain<0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Amgen / AstraZeneca). Who owns AMGN · Who owns AZN
More on Amgen
Further comparisons
Amgen against its closest peers
AstraZeneca against its closest peers
Learn
Questions and answers
Which is bigger, Amgen or AstraZeneca?
By market value, AstraZeneca is the larger: $283.9B against $248.1B for Amgen. By revenue in its latest fiscal year, AstraZeneca is the larger: $58.7B against $36.8B for Amgen.
Which has the higher P/E ratio?
Amgen: 26.6, against 25.9 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Amgen: 24.7%, against 23.4% for AstraZeneca. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Amgen: $54.6B, against $29.6B for AstraZeneca. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Amgen and AstraZeneca?
In their latest 13F filings, Primecap team, Ken Fisher and Dodge & Cox team hold both.
Cite this page
Funkfolio, “Amgen vs AstraZeneca”, data as of 17 November 2026. https://funkfolio.com/compare/amgn-vs-azn
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.